<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112524">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01769066</url>
  </required_header>
  <id_info>
    <org_study_id>Gefitinib-2009-cjh</org_study_id>
    <nct_id>NCT01769066</nct_id>
  </id_info>
  <brief_title>Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC</brief_title>
  <official_title>Random Open Exploratory Clinical Research of Sequential Gefitinib With Pemetrexed/Platinum Compare With Pemetrexed/Platinum Treatment for Advanced Non-small Cell Lung Cancer Exploratory Clinical Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to explore the Clinical Value of Sequential Gefitinib With
      Pemetrexed/Platinum compare with Pemetrexed/Platinum for Advanced NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to 2 groups
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2009</start_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>12 weeks of non-progression rate</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Sequential Gefitinib With Pemetrexed/Platinum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed	IV 500 mg/m2 ，DAY2 DDP	IV 75mg/m2 ，DAY1 OR CAP	IV AUC 5,DAY1 Gefitinib	PO.	250mg	DAY3-16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pemetrexed/Platinum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed	IV 500 mg/m2 ，DAY2 DDP	IV 75mg/m2 ，DAY1 OR CAP	IV AUC 5,DAY1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequential Gefitinib With Pemetrexed/Platinum</intervention_name>
    <arm_group_label>Sequential Gefitinib With Pemetrexed/Platinum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed/Platinum</intervention_name>
    <arm_group_label>Pemetrexed/Platinum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18~70 years

          2. Patients who were diagnosed by the histologic, cytologic diagnosis of IIIb-IV
             non-small cell lung cancer

          3. Presence of at least one index lesion measurable by CT scan or MRI

          4. Ecog0-1

          5. Expected life time longer than 12 weeks

          6. Normal laboratory values:

               -  leucocyte ≥ 4×109/L

               -  neutrophil ≥ 1.5×109/L

               -  platelet ≥ 100×109/L

               -  Hemoglobin ≥ 10g/L

               -  ALT and

               -  AST ≤ 2.5×ULN (≤ 5×ULN if liver metastasis)

          7. Signed written informed consent

        Exclusion Criteria:

          -  Patients have used drugs according to protocol

          -  Patients were allergic to pemetrexed or cisplatin

          -  Patients received radiotherapy or other biological treatment 4 weeks before the trial

          -  Uncontrolled hydrothorax or hydropericardium

          -  neuropathy toxicity ≥ CTC 3

          -  Severe symptomatic heart disease

          -  Active upper gastrointestinal ulcer or digestive disfunction

          -  Severe infection or metabolic disfunction

          -  Patients with other malignant tumor

          -  Uncontrolled brain metastases

          -  Patients have accepted other clinical trials

          -  Female patients during their pregnant and lactation period, or patients without
             contraception
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang jian hua, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer hospital Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 12, 2013</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chang Jian Hua</investigator_full_name>
    <investigator_title>Deputy director of department of medical oncology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
